NMS · Biotechnology

GERN (GERN) Stock

$1.34 -4.29% NMS: GERN Healthcare

Valuation

MetricValue
Price$1.34
Market Cap$859.64M
P/E Ratio23.17
P/B Ratio4.06
P/S Ratio4.12
EPS (TTM)$0.06
52-Week High$2.01
52-Week Low$1.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-27.07%
ROA-4.00%
ROCE-23.89%
Gross Margin-29.35%
Operating Margin-29.35%
Net Margin-35.48%
Debt/Equity1.10
Current Ratio4.64

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$77.0M$184.0M
Operating Profit$-114.0M$-139.0M$-194.0M$-174.0M$-54.0M
Net Profit$-116.0M$-142.0M$-184.0M$-175.0M$-86.0M
EPS$-0.37$-0.37$-0.32$-0.27$-0.13
Op Margin-8183.7%-23246.6%-81832.9%-225.6%-29.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$226.0M$191.0M$394.0M$594.0M$571.0M
Total Liabilities$100.0M$111.0M$146.0M$313.0M$345.0M
Cash$35.0M$57.0M$70.0M$79.0M$79.0M
Borrowings$55.0M$56.0M$86.0M$122.0M$252.0M

Latest News

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman GlobeNewswire · Jul 15, 2026 Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 14, 2026 Geron (GERN) Grants Inducement Stock Options to New Employees Insider Monkey · Jul 14, 2026 Geron Announces Appointment of Chinmaya Rath as Chief Business Officer GlobeNewswire · Jul 13, 2026 Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? Zacks · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-96.0M$-127.0M$-168.0M$-219.0M$-111.0M
Investing Cash Flow$72.0M$62.0M$-181.0M$-107.0M$107.0M
Financing Cash Flow$3.0M$17.0M$119.0M$159.0M$0
Net Cash Flow$25.0M$22.0M$14.0M$10.0M$-1.0M
Free Cash Flow$-96.0M$-128.0M$-169.0M$-219.0M$-111.0M

Valuation & Return Ratios

MetricValue
PEG Ratio45.56
EV / EBITDA—
FCF Yield-15.62%
Quick Ratio6.78
Interest Coverage-1.64
Return 1Y9.02%
Return 3Y-52.15%
Return 5Y10.40%

Ownership

Insiders Held0.08%
Institutions Held79.65%
Institutions Float Held79.71%
Institutional HolderSharesReport Date
RA Capital Management, L.P.63,771,3662026-03-31
Blackrock Inc.47,319,7792026-03-31
Soleus Capital Management, L.P.41,508,6592026-03-31
Deep Track Capital, Lp31,720,2782026-03-31
State Street Corporation30,497,1832026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARVN $8.02 -3.43% -6.94 $517.14M 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
DAWNDay One Biopharmaceuticals, Inc. $21.53 +0.00% -20.70 $2.22B 0.00%
LENZ $5.05 +1.10% -3.18 $158.34M 0.00%
REPL $11.92 +0.08% -1.66 $1.00B 0.00%

About GERN

GERN is led by CEO Harout Semerjian, employs 229 people, headquartered in US, publicly traded since 1996.

GERN stock trades at $1.34 with a market capitalization of $859.64M. The stock is valued at a price-to-earnings (P/E) ratio of 23.17, price-to-book of 4.06, price-to-sales of 4.12. Over the past 52 weeks the stock has ranged between $1.04 and $2.01, and currently trades 33.3% below its 52-week high.

On profitability, GERN generates a return on equity (ROE) of -27.07%, return on capital employed of -23.89%, an operating margin of -29.35%, a net profit margin of -35.48%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides